

Computational Analysis of Natural Products from *Cyperus rotundus* for Osteoarthritis

Km Shashiprabha Singh^{1*}, Dr. Nalini Kanta Sahoo¹

^{1*},¹Faculty of Pharmaceutical Sciences, Rama University, Kanpur, Uttar Pradesh, India

*Corresponding author:-

Km Shashiprabha Singh

Faculty of Pharmaceutical Sciences, Rama University, Kanpur, Uttar Pradesh, India.

Email id- shashiprabhasingh991@gmail.com

Abstract

Osteoarthritis (OA) is a chronic joint disease marked by cartilage breakdown, inflammatory changes in the synovium, oxidative stress, and gradual joint dysfunction. Although there are available treatments such as NSAIDs, corticosteroids, and pain relievers, their prolonged use often results in undesirable side effects, ineffectiveness, and inability to modify the disease course. Therefore, natural products and their active components have become increasingly popular as safe and multi-targeted treatment options. *Cyperus rotundus*, commonly referred to as nut grass or purple nutsedge, is a highly valued medicinal plant extensively employed in folk medicine for conditions such as inflammation, pain, digestive ailments, and oxidative stress-induced illnesses. It has been discovered that phytochemical analysis of this plant includes flavonoids, sesquiterpenes, phenolic compounds, alkaloids, terpenoids, and essential oils that exhibit potent anti-inflammatory and antioxidant properties. Approaches like molecular docking, molecular dynamics, network pharmacology, and ADMET prediction have been instrumental in identifying phytochemicals that target key osteoarthritis mediators, such as COX-2, TNF- α , IL-1 β , MMPs, NF- κ B, and MAPK pathways. This review focuses on the phytochemistry, pharmacological effects, and computational analysis of phytoconstituents from *Cyperus rotundus* as possible anti-osteoarthritic drugs. This review also provides an insight into the drug-likeness and toxicity assessment, current issues, and future outlook of computational research.

Keywords: Phytochemicals; Cartilage degeneration; Natural products; Cytokine modulation; *In-silico* pharmacology.

1. Introduction

Osteoarthritis (OA) is the most common form of chronic degenerative joint disease that affects millions of people across the world, especially elderly patients. It is a disease characterized by

the progressive deterioration of the articular cartilage, inflammation of the synovium, formation of osteophytes, subchondral bone changes, and loss of joint flexibility [1]. Osteoarthritis usually affects weight-bearing joints such as knee joints, hip joints, spine joints, and hand joints, causing chronic pain, stiffness, swelling, and poor quality of life. The etiology of osteoarthritis is complicated and is influenced by aging, mechanical factors, obesity, genetic predisposition, metabolic imbalance, oxidative stress, and inflammation [2]. Recent scientific advances in molecular biology have shown that osteoarthritis is not only a degenerative disease but also an inflammatory disease that results from the activation of cytokines and catabolic pathways [3]. Some of the major pro-inflammatory mediators include tumor necrosis factor-alpha (TNF- α), interleukin-1 beta (IL-1 β), interleukin-6 (IL-6), cyclooxygenase-2 (COX-2), matrix metalloproteinases (MMPs), nuclear factor-kappa B (NF- κ B), and mitogen-activated protein kinase (MAPK) [4].

Currently, the treatment strategies for osteoarthritis are limited to symptom relief by NSAIDs, corticosteroids, analgesics, and surgery. While these treatments are effective in reducing pain and inflammation, their prolonged usage causes several side effects, such as gastrointestinal, cardiac, renal, hepatic toxicity, and dependence on drugs [5]. Also, none of the existing drugs can prevent cartilage destruction. All these factors have led to an increased interest in the discovery of new and safer multitarget agents obtained from natural sources. Natural products contain a wide range of phytochemicals that have anti-inflammatory, antioxidant, analgesic, and chondroprotective properties. Among these, *Cyperus rotundus* has been studied extensively owing to its widespread usage in various traditional medicines like Ayurveda, Siddha, and Traditional Chinese Medicine [6].

Cyperus rotundus is a member of the Cyperaceae family and is popularly referred to as nut grass or purple nutsedge. Various parts of the plant, especially its rhizomes and tubers, have been utilized traditionally in the treatment of pain, inflammation, fever, gastrointestinal ailments, arthritis, menstrual irregularities, and conditions associated with oxidative stress [7]. The various phytochemical studies conducted on the plant have revealed several active constituents, which include flavonoids, sesquiterpenes, alkaloids, phenols, terpenoids, tannins, and essential oils. Some of the key phytochemicals found in the plant include *cyperene*, *cyperotundone*, *quercetin*, *kaempferol*, *patchoulone*, and *β -sitosterol*. All these compounds possess excellent anti-inflammatory and antioxidant activities. They inhibit oxidative stress, cytokines, and matrix metalloproteinases [8].

The combination of computational biology and bioinformatics in the field of natural products has brought about a breakthrough in modern drug discovery processes. Computational methods such as molecular docking, molecular dynamics simulation, QSAR analysis, network pharmacology, and ADMET prediction offer efficient ways to screen for possible leads among plant-based medicines [9]. These methods can be used to predict ligand-receptor interaction, binding affinity, pharmacokinetics, toxicity, and multitarget actions of the compounds before their experimental validation [10]. In osteoarthritis studies, the use of computational methods has gained popularity as a means of screening for phytochemicals targeting inflammatory and cartilage degradation factors such as COX-2, TNF- α , IL-1 β , MMP-13, NF- κ B, and MAPK signaling proteins. Thus, the phytochemicals of *Cyperus rotundus* could be useful multitarget agents in the design of safe anti-osteoarthritic drugs [11].

Although there is increasing research on osteoarthritis treatment using natural products, literature reviews on the computational study of phytochemicals from *Cyperus rotundus* have not been reported comprehensively. Hence, this review attempts to provide an overview of the phytochemistry, pharmacological properties, and computational studies on *Cyperus rotundus* as a potential source of drugs for treating osteoarthritis [12]. The paper will also explore the molecular target identification, anti-inflammatory mechanisms, drug-likeness prediction, ADMET evaluation, challenges, and future directions for natural product-based multitarget therapies for osteoarthritis [13].




Figure 1. Natural Product-Based Computational Discovery of Phytochemicals from *Cyperus rotundus* for Treating Osteoarthritis [14].

A schematic representation of the natural product-based computational discovery of phytochemicals from *Cyperus rotundus* as promising multitarget therapeutic molecules for treating Osteoarthritis. This figure emphasizes the conventional uses of *Cyperus rotundus* and its significant phytochemicals, which include quercetin, kaempferol, cyperene, cyperotundone, and β -sitosterol. The figure also illustrates various computational techniques such as molecular docking, molecular dynamics simulation, network pharmacology, and ADMET prediction to predict the interaction between the phytochemicals and osteoarthritis-related inflammatory targets, including COX-2, TNF- α , IL-1 β , MMP-13, NF- κ B, and MAPK proteins.

2. Computational Study of Phytochemicals of *Cyperus rotundus*

The use of computational methods like molecular docking and network pharmacology plays a significant role in discovering phytochemicals that can be used to target diseases, such as osteoarthritis [15]. Molecular docking predicts the interaction between bioactive molecules and inflammatory targets, including COX-2, TNF- α , IL-1 β , MMPs, NF- κ B, and MAPK signaling proteins. Phytochemicals found in *Cyperus rotundus*, such as flavonoids, sesquiterpenes, sterols, and phenolic compounds, show anti-inflammatory and antioxidant properties through in silico studies [16].

2.1 Docking Analysis Against Inflammatory Targets

Several phytochemicals found in *Cyperus rotundus* show high binding affinity towards inflammatory proteins related to osteoarthritis development. This may play a role in suppressing inflammatory mediators, oxidative stress, cartilage destruction, and synovial inflammation. Quercetin, which is one of the most important flavonoids found in *Cyperus rotundus*, shows high binding affinity towards COX-2, NF- κ B, and TNF- α proteins due to hydrogen bonding and hydrophobic interaction [17]. The compound has been shown to possess anti-inflammatory and antioxidant properties. Sesquiterpenes like cyperene and cyperotundone have been reported to inhibit inflammation and the action of cartilage-degrading enzymes. They can also inhibit IL-1 β -mediated inflammation and control the expression of matrix metalloproteinases that cause cartilage breakdown [18].

Beta-sitosterol is known to have potent anti-inflammatory effects by inhibiting the action of COX-2 and oxidative stress. Beta-sitosterol may also be effective in stabilizing cellular

membranes and reducing inflammation in joint tissues. Flavonoids, including kaempferol, have high binding affinity for NF- κ B and MAPK pathway proteins. They can be used to inhibit the formation of inflammatory cytokines and prevent cartilage breakdown and apoptosis in chondrocytes [19].

3. ADMET and Drug-Likeness Assessment

The drug-likeness and ADMET assessment process helps to identify the potential therapeutic agents from the natural products found in *Cyperus rotundus* [20]. The rule of five, which is a predictive approach, can be used to assess the oral bioavailability of an agent based on its molecular weight, hydrogen bond donors, hydrogen bond acceptors, and log P values. Some of the phytochemicals obtained from *Cyperus rotundus* have been found to fulfill these criteria, thus making them drug-like. In silico toxicity prediction analysis can be carried out to predict toxic effects such as hepatotoxicity, mutagenicity, carcinogenicity, and cardiotoxicity [21].

4. Challenges in Translational Research

In spite of promising computational results, several challenges obstruct the translational potential of *Cyperus rotundus* phytochemicals for use as effective osteoarthritis drugs. These include inadequate clinical validation, poor bioavailability, lack of pharmacokinetic information, and insufficient knowledge about phytochemical composition [22]. Variability arising due to different extraction procedures, geographical settings, and plant sources is another challenge that needs to be addressed. Moreover, there is a need for more molecular dynamics analysis, along with a standardized formulation of phytochemicals [23].

5. Future Perspectives

Future research should concentrate on utilizing computational methods, along with experimental validation, for rapid anti-osteoarthritic drug discovery using *Cyperus rotundus* [24]. Artificial intelligence-driven drug discovery, QSAR modeling via machine learning, and systems pharmacology can contribute to identifying powerful multitarget phytochemicals. Conducting in vitro and animal experiments and clinical trials is essential to validate the effectiveness and safety of phytochemicals for treating osteoarthritis. Furthermore, nanotechnology-assisted drug delivery and nanoformulation of phytochemicals could be explored in future studies [25].

Conclusion

Cyperus rotundus shows considerable therapeutic potential against osteoarthritis owing to its extensive phytochemistry and wide range of pharmacological actions, such as anti-inflammatory, antioxidant, analgesic, and chondroprotective effects. Studies using computational approaches have shown that key phytochemicals like quercetin, kaempferol, cyperene, cyperotundone, and β -sitosterol can strongly interact with several inflammatory mediators and pathways responsible for osteoarthritis pathogenesis, including COX-2, TNF- α , NF- κ B, IL-1 β , and the MAPK pathway. Such compounds might help to minimize oxidative stress, reduce cytokine production, inhibit cartilage breakdown, and prevent tissue damage.

Additionally, the use of computational methods like molecular docking, network pharmacology, and ADMET analysis has greatly facilitated the process of identifying novel bioactive compounds from medicinal plants and understanding their multitarget mechanisms of action. Despite the current positive results, further in vitro, in vivo, and clinical trials will be needed to confirm the efficacy, safety, bioavailability, and pharmacokinetics of these phytochemicals. In summary, *Cyperus rotundus* is a promising plant for the development of safe and efficient multitarget drugs for osteoarthritis treatment.

References

- 1) Hunter DJ, Bierma-Zeinstra S. Osteoarthritis. *Lancet*. 2019;393(10182):1745-59. doi:10.1016/S0140-6736(19)30417-9.
- 2) Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: a review. *JAMA*. 2021;325(6):568-78. doi:10.1001/jama.2020.22171.
- 3) Loeser RF, Goldring SR, Scanzello CR, Goldring MB. Osteoarthritis: a disease of the joint as an organ. *Arthritis Rheum*. 2012;64(6):1697-707. doi:10.1002/art.34453.
- 4) Robinson WH, Lepus CM, Wang Q, Raghu H, Mao R, Lindstrom TM, et al. Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis. *Nat Rev Rheumatol*. 2016;12(10):580-92. doi:10.1038/nrrheum.2016.136.

- 5) Glyn-Jones S, Palmer AJR, Agricola R, Price AJ, Vincent TL, Weinans H, et al. Osteoarthritis. *Lancet*. 2015;386(9991):376-87. doi:10.1016/S0140-6736(14)60802-3.
- 6) Goldring MB, Otero M. Inflammation in osteoarthritis. *Curr Opin Rheumatol*. 2011;23(5):471-8. doi:10.1097/BOR.0b013e328349c2b1.
- 7) Mobasheri A, Rayman MP, Gualillo O, Sellam J, van der Kraan P, Fearon U. The role of metabolism in the pathogenesis of osteoarthritis. *Nat Rev Rheumatol*. 2017;13(5):302-11. doi:10.1038/nrrheum.2017.50.
- 8) Bijlsma JWJ, Berenbaum F, Lafeber FPJG. Osteoarthritis: an update with relevance for clinical practice. *Lancet*. 2011;377(9783):2115-26. doi:10.1016/S0140-6736(11)60243-2.
- 9) Babiaka SB, Moumbock AFA, Günther S, Ntie-Kang F. Natural products in *Cyperus rotundus* L. (Cyperaceae): an update of the chemistry and pharmacological activities. *RSC Adv*. 2021;11(14):8352-63. doi:10.1039/D1RA00478F.
- 10) Xue BX, He RS, Lai JX, et al. Phytochemistry, data mining, pharmacology, toxicology and the analytical methods of *Cyperus rotundus* L. (Cyperaceae): a comprehensive review. *Phytochem Rev*. 2023;22:1353-98. doi:10.1007/s11101-023-09870-3.
- 11) Rocha FG, Brandenburg MM, Pawloski PL, Soley BS, Costa SCA, Meinerz CC, et al. Preclinical study of the topical anti-inflammatory activity of *Cyperus rotundus* L. extract in models of skin inflammation. *J Ethnopharmacol*. 2020;254:112709. doi:10.1016/j.jep.2020.112709.
- 12) Bezerra J JL, Pinheiro AAV, de Oliveira AFM. Cyperaceae species used for the treatment of inflammation: a review of ethnomedicinal, pharmacological, toxicological, and phytochemical evidence. *S Afr J Bot*. 2023;154:170-89. doi:10.1016/j.sajb.2022.09.020.
- 13) Ibrahim SRM, Mohamed GA, Alshali KZ, Al Haidari RA, El-Kholy AA, Zayed MF. Lipoxygenase inhibitors flavonoids from *Cyperus rotundus* aerial parts. *Braz J Pharmacogn*. 2018;28(5):574-8. doi:10.1016/j.bjp.2018.04.002.
- 14) Zhou Z, Yin W. Two novel phenolic compounds from the rhizomes of *Cyperus rotundus* L. *Molecules*. 2012;17(11):12636-41. doi:10.3390/molecules171112636.
- 15) Yang JL, Shi YP. Structurally diverse terpenoids from the rhizomes of *Cyperus rotundus* L. *Planta Med*. 2012;78(1):59-64. doi:10.1055/s-0031-1280347.

- 16) Dang GK, Parekar RR, Kamat SK, Scindia AM, Rege NN. Anti-inflammatory activity of *Phyllanthus emblica*, *Plumbago zeylanica* and *Cyperus rotundus* in acute models of inflammation. *Phytother Res*. 2011;25(6):904-8. doi:10.1002/ptr.3344.
- 17) Wang M, Yang TT, Rao Y, Wang ZM, Dong X, Zhang LH, et al. A review on traditional uses, phytochemistry, pharmacology, toxicology and the analytical methods of the genus *Nardostachys*. *J Ethnopharmacol*. 2021;280:114446. doi:10.1016/j.jep.2021.114446.
- 18) Li H, Wang D, Yuan Y, Min J. New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. *Arthritis Res Ther*. 2017;19(1):248. doi:10.1186/s13075-017-1454-8.
- 19) Henrotin Y, Pesesse L, Lambert C. Targeting the synovial angiogenesis as a novel treatment approach to osteoarthritis. *Ther Adv Musculoskelet Dis*. 2014;6(1):20-34. doi:10.1177/1759720X13505445.
- 20) Zhang L, Zhang L, Zhou D, Bao Y, Chen Z. α -Cyperone protects chondrocytes against IL-1 β -induced inflammation and extracellular matrix degradation. *Int Immunopharmacol*. 2021;97:107693. doi:10.1016/j.intimp.2021.107693.
- 21) Wang C, Zhou X, Xu H, Shi X, Zhao J, Yang M, et al. α -Cyperone attenuates osteoarthritis through suppression of NF- κ B and MAPK signaling pathways. *Biomed Pharmacother*. 2021;140:111716. doi:10.1016/j.biopha.2021.111716.
- 22) Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Sci Rep*. 2017;7:42717. doi:10.1038/srep42717.
- 23) Lipinski CA. Lead- and drug-like compounds: the rule-of-five revolution. *Drug Discov Today Technol*. 2004;1(4):337-41. doi:10.1016/j.ddtec.2004.11.007.
- 24) Lionta E, Spyrou G, Vassilatis DK, Cournia Z. Structure-based virtual screening for drug discovery: principles, applications and recent advances. *Curr Top Med Chem*. 2014;14(16):1923-38. doi:10.2174/1568026614666140929124445.
- 25) Sliwoski G, Kothiwale S, Meiler J, Lowe EW Jr. Computational methods in drug discovery. *Pharmacol Rev*. 2014;66(1):334-95. doi:10.1124/pr.112.007336.